check_circleStudy Completed

Menopause, Hot Flashes, Night Waking

Bayer Identifier:
21686
ClinicalTrials.gov Identifier:
NCT03596762
EudraCT Number:
2018-002763-26
EU CT Number:
Not Available
A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

Trial purpose

The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.

Key Participants Requirements

Sex

Female

Age

40 - 65 Years
  • Key :

    - Postmenopausal

    - Body mass index between 18 and 38 kg/m2, inclusive

    - Subject experiences moderate or severe hot flashes

    Key
  • - Inability to comply with the use of prohibited and allowed medications as described in the protocol.

    - Any prior or ongoing history of clinically relevant drug or alcohol abuse within 12 months of Screening.

    - Any clinically significant prior or ongoing history of arrhythmias, either determined through clinical history or on ECG evaluation.

    - Any clinically significant abnormal laboratory test result(s) measured at Screening.

    - Any active ongoing condition that could have caused difficulty in interpreting vasomotor symptoms.

    - Uncontrolled hypertension.

    - A history or hyperthyroidism, hypothyroidism or abnormal thyroid function tests at Screening. Treated hypothyroidism with normal thyroid function test results at Screening is acceptable.

Trial summary

Enrollment Goal
199
Trial Dates
November 2018 - November 2019
Phase
Phase 2
Could I Receive a placebo
Yes
Products
Lynkuet (Elinzanetant, BAY3427080)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Study Site 12Mesa, 85209, United States
Study Site 19San Diego, 92108, United States
Study Site 13Aventura, 33180, United States
Study Site 15Lake Worth, 33461, United States
Study Site 18Atlanta, 30328, United States
Study Site 16New Orleans, 70125, United States
Study Site 10Boston, 02114, United States
Study Site 11Boston, 02115, United States
Study Site 17Las Vegas, 89128, United States
Study Site 14Houston, 77054, United States
Study Site 50Red Deer, Canada
Study Site 51Mission, Canada
Study Site 54Guelph, Canada
Study Site 52Scarborough, Canada
Study Site 53Toronto, Canada
Study Site 37Blackpool, United Kingdom
Study Site 34Cannock, United Kingdom
Study Site 31Glasgow, United Kingdom
Study Site 39Leeds, United Kingdom
Study Site 38Liverpool, United Kingdom
Study Site 30London, United Kingdom
Study Site 36Manchester, United Kingdom
Study Site 33Poole, United Kingdom
Study Site 32Southport, United Kingdom
Study Site 35Stockton-on-Tees, United Kingdom

Primary Outcome

  • Mean change from baseline in mean daily frequency of moderate and severe hot flushes from baseline to Week 4
    Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
    date_rangeTime Frame:
    From baseline to Week 4
  • Mean change from baseline in mean daily frequency of moderate and severe hot flushes from baseline to Week 12
    Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
    date_rangeTime Frame:
    From baseline to Week 12
  • Mean change from baseline in mean severity of moderate and severe hot flushes from baseline to Week 4
    Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
    date_rangeTime Frame:
    From baseline to Week 4
  • Mean change from baseline in mean severity of moderate and severe hot flushes from baseline to Week 12
    Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3] / (total number of moderate to severe hot flushes over 7 days). Severity was graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
    date_rangeTime Frame:
    From baseline to Week 12

Secondary Outcome

  • Mean change from baseline in frequency of mean daily moderate and severe hot flushes from baseline to Weeks 1, 2, 8 and 16
    Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
    date_rangeTime Frame:
    From baseline to Weeks 1, 2, 8 and 16
  • Mean change from baseline in mean severity of moderate and severe hot flushes from baseline to Weeks 1, 2, 8 and 16
    Participants recorded daily in their diary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
    date_rangeTime Frame:
    From baseline to Weeks 1, 2, 8 and 16
  • Mean change from baseline in mean daily frequency of all hot flushes from baseline to Weeks 1, 2, 4, 8, 12 and 16
    Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.
    date_rangeTime Frame:
    From baseline to Weeks 1, 2, 4, 8, 12 and 16
  • Mean change from baseline in mean severity of all hot flushes from baseline to Weeks 1, 2, 4, 8, 12 and 16
    Participants recorded daily in their diary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
    date_rangeTime Frame:
    From baseline to Weeks 1, 2, 4, 8, 12 and 16
  • Mean change from baseline in the mean daily hot flush score (frequency x severity) at Weeks 1, 2, 4, 8, 12 and 16
    Mean daily Hot Flushes score = Sum of (frequency x severity) filled in the diary during the last 7 days (with at least one available data in the evening and/or morning) divided by 7. Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
    date_rangeTime Frame:
    From baseline to Weeks 1, 2, 4, 8, 12 and 16
  • Number of participants with ≥50% and ≥80% reduction from baseline in mean daily hot flushes frequency at Week 12
    The percent change from baseline at a visit Week 12 was calculated. Percent change = (change from baseline in mean daily frequency of moderate and severe hot flushes from baseline to Week 12 / Mean daily frequency of moderate and severe hot flushes at baseline) * 100. A participant was considered as a responder with a reduction of ≥50% (or ≥80%) if the percent change was ≤-50 (or ≤-80).
    date_rangeTime Frame:
    Week 12
  • Mean change from baseline in number of all night-time awakenings (NTA) at Weeks 1, 2, 4, 8, 12 and 16
    Participants were provided with an eDiary to document the number of night-time awakenings (NTA). Each evening, participants recorded the total number of hot flushes of each severity experienced that day since waking. Each morning upon waking, subjects recorded the number of times they woke up in the night and the total number of hot flushes of each severity experienced during the night.
    date_rangeTime Frame:
    From baseline to Weeks 1, 2, 4, 8, 12 and 16
  • Mean change from baseline in mean daily number of NTAs secondary to hot flushes at Weeks 1, 2, 4, 8, 12 and 16
    Subjects were provided with an eDiary to document the number of night-time awakenings (NTA). Each evening, subjects recorded the total number of hot flashes of each severity experienced that day since waking. Each morning upon waking, subjects recorded the number of times they woke up in the night and the total number of hot flushes of each severity experienced during the night. Night-time awakenings secondary to hot flashes corresponded to severe hot flash recorded on the morning diary, and all NTAs corresponded to the data recorded in the “Total number of times you woke up last night?” field from the eDiary recorded in the morning. Number of NTAs secondary to hot flushes could not be higher than the number of all NTAs.
    date_rangeTime Frame:
    From baseline to Weeks 1, 2, 4, 8, 12 and 16
  • Change from baseline in the global and individual domain scores of the Pittsburgh Sleep Quality Index (PSQI) at Weeks 4, 8, 12 and 16
    The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. The PSQI uses 19 individual items to generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction, each scored 0 (no difficulty) to 3 (severe difficulty). The sum of scores for these seven components yields one global score (range 0 to 21). Higher scores indicated worse sleep quality.
    date_rangeTime Frame:
    From baseline to Weeks 4, 8, 12 and 16
  • Change from baseline in the Insomnia Severity Index (ISI) score at Weeks 4, 8, 12 and 16
    The ISI is a brief self-report questionnaire assessing the nature, severity, and impact of insomnia. The ISI comprises seven items assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Participants rated each item on a scale of 0 to 4, yielding a total score ranging from 0 to 28. The total score was calculated by adding the scores for all seven items. Higher scores indicated severe insomnia.
    date_rangeTime Frame:
    From baseline to Weeks 4, 8, 12 and 16
  • Change from baseline in the hot flush related daily interference scale (HFRDIS) scores at Weeks 2, 4, 8, 12 and 16
    The HFRDIS is a 10-item, self-report questionnaire assessing the impact of hot flushes on a woman’s life during the past week. For each of the 10 items, participants rated how much hot flushes had interfered with that aspect of their life on a scale of 0 (not at all) to 10 (very much so). The total score was calculated by adding the scores for all 10 items. Higher scores indicated greater interference.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
  • Change from baseline in the Menopause-specific Quality-of-Life questionnaire Intervention Version (MenQoL-I) scores at Weeks 4, 8, 12 and 16
    The MenQoL-I is a validated questionnaire used to measure condition-specific quality of life in menopausal women. It is composed of 32 items across four domains (physical, vasomotor, psychosocial and sexual). For each item, participants recorded whether they had experienced the problem in the past month, and if so, they rated how bothered they were by the problem on a scale of 0 (not at all bothered) to 6 (extremely bothered). The item scores were converted to a score ranging from 1 to 8. Domain scores are calculated by averaging the converted individual item scores (range 1-8) related to the respective domain. (Domains: Vasomotor - items 1 to 3, Psychosocial – items 4 to 10, Physical- items 11- to 26, Sexual – items 27 to 29). For a MENQOL total score the aggregated mean of the mean domain scores is calculated. Higher scores indicate greater bother.
    date_rangeTime Frame:
    From baseline to Weeks 4, 8, 12 and 16;
  • Change from baseline in the Beck Depression Inventory II (BDI-II) scores at Weeks 2, 4, 8, 12 and 16
    The BDI-II is a 21-item questionnaire assessing the intensity of depressive symptoms over the past 2 weeks. It is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Participants rated each item on a scale of 0 to 3 to give a total score ranging from 0 to 63, with a higher score suggesting more severe depressive symptoms.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
  • Plasma Elinzanetant Concentrations at Weeks 2, 4, 8 ,12
    Blood samples for analysis of plasma elinzanetant concentrations were collected at Weeks 2, 4, 8, and 12. A small number of participants had elinzanetant concentrations below the LOQ for the assay (1.5 ng/mL) at two or more visits (three participants in each of the 40 mg, 120 mg, and 160 mg groups, four in 80 mg group), indicating that these subjects were non compliant with treatment.
    date_rangeTime Frame:
    At Weeks 2, 4, 8 ,12
  • Nature and severity of adverse events
    A Treatment-Emergent Adverse Events (TEAE) is defined as any adverse event (serious and non-serious) with the onset date on or after the date of first dosing with study treatment. Safety Analysis Set.
    date_rangeTime Frame:
    Up to Week 16
  • Withdrawals due to an adverse event
    A Treatment-Emergent Adverse Events (TEAE) is defined as any adverse event (serious and non-serious) with the onset date on or after the date of first dosing with study treatment.
    date_rangeTime Frame:
    Up to Week 16
  • Number of subjects used concomitant medications
    A concomitant medication is defined as any medication used on or after date and time of first randomised treatment. All concomitant medications taken during the study were recorded in the eCRF. Any medication that was not specifically prohibited was allowed. (1) Antidiarrheals, intestinal antiinflammatory/antiinfective agents.
    date_rangeTime Frame:
    Up to Week 16
  • Change from baseline in vital signs (systolic blood pressure) at Weeks 2, 4, 8, 12 and 16
    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
  • Change from baseline in vital signs (diastolic blood pressure) at Weeks 2, 4, 8, 12 and 16
    Vital signs, including systolic and diastolic blood pressure were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
  • Change from baseline in vital signs (pulse rate) at Weeks 2, 4, 8, 12 and 16
    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
  • Change from baseline in vital signs (temperature) at Weeks 2, 4, 8, 12 and 16
    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
  • Change from baseline in vital signs (weight) at Weeks 2, 4, 8, 12 and 16
    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
  • Change from baseline in vital signs (Body Mass Index ) at Weeks 2, 4, 8, 12 and 16
    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
  • Change from baseline in vital signs (waist circumference) at Weeks 2, 4, 8, 12 and 16
    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
  • Number of subjects with normal electrocardiogram (ECG) findings at each visit
    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Normal ECG was decided by investigator. The findings are presented as Normal ECG.
    date_rangeTime Frame:
    At Weeks 2, 4, 8, 12 and 16
  • Number of subjects with abnormal not clinically significant ECG findings at each visit
    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Abnormal not clinically significant ECG findings were decided by investigator. The findings are presented as Abnormal not clinically significant ECG.
    date_rangeTime Frame:
    At Weeks 2, 4, 8, 12 and 16
  • Number of subjects with abnormal clinically significant ECG findings at each visit
    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Abnormal clinically significant ECG findings were decided by investigator. The findings are presented as Abnormal clinically significant ECG.
    date_rangeTime Frame:
    At Weeks 2, 4, 8, 12 and 16
  • Change from baseline at Weeks 2, 4, 8, 12 and 16 in ECG intervals (RR)
    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject’s medical record. In categories the number of subjects analyzed (N) for each week is mentioned for each reporting group respectively.
    date_rangeTime Frame:
    At Weeks 2, 4, 8, 12 and 16
  • Change from baseline at Weeks 2, 4, 8, 12 and 16 in ECG intervals (PR)
    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject’s medical record.
    date_rangeTime Frame:
    At Weeks 2, 4, 8, 12 and 16
  • Change from baseline at Weeks 2, 4, 8, 12 and 16 in ECG intervals (QT)
    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject’s medical record.
    date_rangeTime Frame:
    At Weeks 2, 4, 8, 12 and 16
  • Change from baseline at Weeks 2, 4, 8, 12 and 16 in ECG intervals (QTc)
    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject’s medical record. QTc: QT corrected interval.
    date_rangeTime Frame:
    At Weeks 2, 4, 8, 12 and 16
  • Change from baseline at Weeks 2, 4, 8, 12 and 16 in ECG intervals (QTcF)
    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject’s medical record. QTcF: QT interval with Fridericia’s correction.
    date_rangeTime Frame:
    At Weeks 2, 4, 8, 12 and 16
  • Number of subjects with absolute QTcF values by category at each visit: ≤450, >450 to ≤480, >480 to ≤500, >500 msec
    Absolute QTcF values reported.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
  • Number of subjects with change from baseline in ECG QTcF values by category at Weeks 2, 4, 8, 12 and 16: ≤0, >0 to ≤30, >30 to ≤60, >60 msec
    Increase from Baseline overtime was reported.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
  • Change from baseline in the electronic Columbia Suicide Severity Rating Scale (eC-SSRS) at Weeks 4, 12 and 16
    The Columbia Suicide Severity Rating Scale (C-SSRS) is a rating scale created to evaluate suicidality in adults and children over the age of 12. It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The version used was the eC-SSRS, which is a subject-reported version of the scale. Shifts from baseline versus post-baseline to demonstrate changes in categories (cat) were reported using cat 1 (No Suicidal Ideation or Behaviour), cat 2 (Suicidal Ideation) and cat 3 (Suicidal Behaviour).
    date_rangeTime Frame:
    Baseline to Weeks 4, 12 and 16
  • Change from baseline at Weeks 2, 4, 12 and 16 for clinical laboratory parameters Hematology: Erythrocytes
    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 12 and 16 for clinical laboratory parameters Hematology: Hematocrit
    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 12 and 16 in clinical laboratory parameters Hematology: Hemoglobin
    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 12 and 16 in clinical laboratory parameters Hematology: Erythrocytes Mean Corpuscular Volume
    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 12 and 16 in clinical laboratory parameters Hematology: Leukocytes, Platelets, Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils
    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 12 and 16 in clinical laboratory parameters Hematology: Leukocytes, Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils
    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 8, 12 and 16 in clinical laboratory parameters Biochemistry: Sodium, Potassium, Glucose, Urea Nitrogen, Calcium, Phosphate, Bicarbonate, Magnesium and Chloride
    Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 8, 12 and 16 in clinical laboratory parameters Biochemistry: Creatinine and Bilirubin
    Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 8, 12 and 16 in clinical laboratory parameters Biochemistry: Creatinine Kinase, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase and Gamma Glutamyl Transferase
    Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 8, 12 and 16 in clinical laboratory parameters Biochemistry: Protein and Albumin
    Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 8, 12 and 16 in clinical laboratory parameters Biochemistry: Hemoglobin A1C
    Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 8, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 12 and 16 in clinical laboratory parameters Bone: Bone Specific Alkaline Phosphatase and Procollagen 1 N-Terminal Propeptide
    Blood for assessment of bone turnover markers was collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 12 and 16 in clinical laboratory parameters Urinalysis: pH
    Urine for urinalysis was collected and sent to the central laboratory for analysis. Urine pH was measured on a pH scale.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 12 and 16 in clinical laboratory parameters Urinalysis: Specific Gravity
    Urine for urinalysis was collected and sent to the central laboratory for analysis.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 12 and 16 in clinical laboratory parameters Urinalysis: Glucose, Bilirubin, Ketones, Occult Blood, Protein, Urobilinogen and Nitrite
    Urine for urinalysis was collected and sent to the central laboratory for analysis. Clinical relevance was judged by the investigator. Assessment was done using standard laboratory practice. For evaluation of the chemical properties of the urine sample test strips were used which have test pads of chemicals that change color when they come in contact with reagents. The degree of color change correlates with the amount of reagent present. Each color block represents a range of values. Range and direction of scores for reagents nitrite and urobilinogen: negative = normal; positive = abnormal. Range and direction of scores for all other reagents tested: negative = normal; trace, 1+, 2+, 3+ = abnormal, the higher the value, the higher the concentration of the reagent tested.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 12 and 16 in clinical laboratory parameters Urinalysis: Erythrocytes and Leukocytes
    Urine for urinalysis was collected and sent to the central laboratory for analysis. Results are reported according to the amount present in the microscope's field of view at high magnification (/HPF [high-power field]).
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 12 and 16 in clinical laboratory parameters Urinalysis: Hyaline Casts
    Urine for urinalysis was collected and sent to the central laboratory for analysis. Results are reported according to the amount present in the microscope's field of view at low magnification (/LPF [low-power field]).
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes
  • Change from baseline at Weeks 2, 4, 12 and 16 in clinical laboratory parameters Urinalysis: Bacteria, Yeast Cells, Granular Casts, RBC Casts, Waxy Casts and WBC Casts, Calcium Oxalate Crystals, Triple Phosphate Crystals and Uric Acid Crystals
    Urine for urinalysis was collected and sent to the central laboratory for analysis. The evaluation of components in the urine samples such as bacteria, yeast, red blood cells (RBC), white blood cells (WBC), casts and crystals was performed by microscopy. Results are reported according to the amount present in the microscope's field of view at low magnification (/LPF [low-power field]) and high magnification (/HPF [high-power field]). Range and direction of scores microscopic identification of urine components: - Bacteria: none seen, 1+, 2+, 3+,4+, TNTC (too numerous to count). - Other urine components: none seen=normal; few, moderate, many, TNTC = abnormal. The higher the value, the higher the concentration of the component evaluated.
    date_rangeTime Frame:
    From baseline to Weeks 2, 4, 12 and 16
    enhanced_encryption
    Safety Issue:
    Yes

Trial design

A Double-Blind, Randomised, Placebo Controlled, Adaptive Design Study of the Efficacy, Safety and Pharmacokinetics of NT-814 in Female Subjects With Moderate to Severe Vasomotor Symptoms Associated With the Menopause
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
N/A
Assignment
Parallel Assignment
Trial Arms
5

Additional Information

Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.Click here to find information about studies related to Bayer Healthcare products conducted in Europe.